Signal generation in the New Zealand Intensive Medicines Monitoring Programme: A combined clinical and statistical approach

Drug Safety

Volumn 25, Issue 6, 2002, Pages 433-439

  Coulter, David M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; BEZAFIBRATE; CELECOXIB; FLUOXETINE; GEMFIBROZIL; MOCLOBEMIDE; OMEPRAZOLE; SIMVASTATIN; SUMATRIPTAN;

AMNESIA; ANGIONEUROTIC EDEMA; ANXIETY NEUROSIS; ARTHRALGIA; ARTHRITIS; BLOOD DYSCRASIA; COHORT ANALYSIS; CONFERENCE PAPER; CONFUSION; DIARRHEA; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART PALPITATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; IMPOTENCE; KIDNEY FAILURE; NAUSEA; NEW ZEALAND; PAIN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; RASH; SIGNAL DETECTION; SIGNAL PROCESSING; STATISTICAL ANALYSIS; TREMOR; URTICARIA; XEROSTOMIA;

EID: 0036307463     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200225060-00007     Document Type: Conference Paper

References (4)

1. The New Zealand intensive medicines monitoring programme
2. The New Zealand intensive medicines monitoring programme in pro-active safety surveillance
3. Causality classification at pharmacovigilance centres in the European Community
4. A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand intensive medicines monitoring programme (IMMP)